First efficacy and safety results from XELOX1NO16966, a randomised 2x2 factorial phase III trial of - PowerPoint PPT Presentation

1 / 22
} ?>
View by Category
About This Presentation
Title:

First efficacy and safety results from XELOX1NO16966, a randomised 2x2 factorial phase III trial of

Description:

Cancer Research UK Department of Oncology, University ... IV bolus. 5-FU 400mg/m2. IV bolus. Study objectives. Main endpoint = progression-free survival (PFS) ... – PowerPoint PPT presentation

Number of Views:80
Avg rating:3.0/5.0
Slides: 23
Provided by: andre161
Category:

less

Write a Comment
User Comments (0)
About PowerShow.com